pragma.vision Technology observatory & strategic foresight

Verification register Bio, Health & Neuro

Readiness verdict

Lisraya (brepocitinib)

A dated reading of what is claimed, reported, and independently verified in the current evidence.

As of
2026-09-22
Revision
1
Method
v1.3.0

Current reading

Readiness band and full integer triple

AI-assisted assembly · derived results

Readiness band

Mature

Primary summary from verified readiness

Confidence
65% · fresh
Computed at
2026-09-22T00:12:02.437344+00:00
Claimed
100

Public ambition and stated capability

Reported
96

Observed practitioner reporting

Verified
86

Independently supported evidence

Gap
+14

Claimed leads verified

Evidence strength Strong

Decision

What the current evidence supports

Human editorial judgment · 2026-09-22

Adopt with guardrails

Why
Statistically robust, clinically meaningful separation from placebo (TIS 46.5 vs 31.2, P<.001; steroid-sparing) makes it a genuine first-in-class milestone, but the boxed warning and single-trial evidence base warrant caution before over-weighting it.
Next
Track FDA post-marketing surveillance, REMS-equivalent safety reporting, and 12-24 month real-world outcomes before citing this as a template for JAK/TYK2-targeted rare-disease launches.

Constraints

Blockers

No named blocker is present in the current public projection.

Evidence summary

Derived counts

AI-assisted assembly

Total
5
Tier 1
0
Tier 2
3
Tier 3
2
Supports
4
Contradicts
1
Context
0
Latest observed
2026-08-28

Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.

Publication record

Revisions

Initial public reading

  1. 2026-09-21 Reading moved from mature to mature.

Your opinion

Tell us anything.

What works, what doesn't, what's missing — especially about our watches, lenses, and the register itself. Anonymous is fine; leave an email if you'd like a reply.